Acute myeloid leukemia (AML) is a biologically and genetically heterogeneous hematological malignance with an unsatisfactory risk stratification system. Recently, through the novel single-cell RNA sequencing technology, we revealed heterogeneous leukemia myeloblasts in AML. Thyrotropin-releasing hormone (), as biomarkers of CD34CD117 myeloblasts, were found to be prognostic in AML. However, the clinical and genetic features of in AML patients are poorly understood. Here, with data from TCGA AML, was found to be downregulated in patients older than 60 years old, with and mutations, while overexpressed in patients with mutations. This was further validated in three other cohorts of primary AML including Beat AML ( = 223), GSE6891 ( = 461), and GSE17855 ( = 237). Furthermore, we demonstrated that the expression of in AML could be used to improve the ELN 2017 risk stratification system. In conclusion, our preliminary analysis revealed that , a novel biomarker for AML patients, could be used to evaluate the survival of AML.